Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 53 | 2024 | 1037 | 7.470 |
Why?
|
Social Support | 20 | 2024 | 214 | 5.080 |
Why?
|
Postmenopause | 24 | 2024 | 267 | 3.360 |
Why?
|
Social Networking | 9 | 2023 | 20 | 2.890 |
Why?
|
Women's Health | 26 | 2023 | 207 | 2.650 |
Why?
|
Obesity | 23 | 2022 | 855 | 2.180 |
Why?
|
Colorectal Neoplasms | 12 | 2021 | 656 | 2.100 |
Why?
|
Female | 107 | 2024 | 13136 | 2.040 |
Why?
|
Body Mass Index | 25 | 2022 | 974 | 2.010 |
Why?
|
Humans | 115 | 2024 | 18430 | 1.930 |
Why?
|
Middle Aged | 84 | 2024 | 8284 | 1.930 |
Why?
|
Aged | 72 | 2024 | 6417 | 1.770 |
Why?
|
Risk Factors | 49 | 2023 | 3449 | 1.690 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2016 | 249 | 1.500 |
Why?
|
Life Style | 6 | 2020 | 342 | 1.430 |
Why?
|
Proportional Hazards Models | 27 | 2022 | 743 | 1.380 |
Why?
|
Neoplasms | 6 | 2022 | 457 | 1.290 |
Why?
|
Telomere | 6 | 2019 | 19 | 1.270 |
Why?
|
Delivery of Health Care, Integrated | 4 | 2024 | 567 | 1.260 |
Why?
|
Stress, Psychological | 9 | 2024 | 147 | 1.230 |
Why?
|
Social Isolation | 4 | 2022 | 16 | 1.200 |
Why?
|
Time-to-Treatment | 2 | 2024 | 18 | 1.130 |
Why?
|
Neoplasm Staging | 15 | 2024 | 337 | 1.120 |
Why?
|
Diet | 7 | 2022 | 371 | 1.100 |
Why?
|
Dietary Fats | 6 | 2013 | 92 | 1.100 |
Why?
|
Prognosis | 22 | 2020 | 624 | 1.090 |
Why?
|
Body Weight | 7 | 2021 | 223 | 1.080 |
Why?
|
Adult | 46 | 2024 | 7910 | 1.040 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2015 | 57 | 0.980 |
Why?
|
Estrogens | 3 | 2013 | 73 | 0.960 |
Why?
|
Feeding Behavior | 3 | 2014 | 168 | 0.920 |
Why?
|
Dairy Products | 3 | 2013 | 23 | 0.910 |
Why?
|
Quality of Life | 8 | 2016 | 529 | 0.910 |
Why?
|
Prospective Studies | 28 | 2023 | 1314 | 0.900 |
Why?
|
Coronary Artery Disease | 4 | 2016 | 133 | 0.900 |
Why?
|
Body Size | 2 | 2020 | 31 | 0.850 |
Why?
|
Colonic Neoplasms | 3 | 2020 | 157 | 0.840 |
Why?
|
Cohort Studies | 26 | 2022 | 2672 | 0.790 |
Why?
|
Cardiovascular Diseases | 9 | 2024 | 630 | 0.770 |
Why?
|
Asian Americans | 2 | 2020 | 182 | 0.760 |
Why?
|
Incidence | 17 | 2022 | 1314 | 0.750 |
Why?
|
Rectal Neoplasms | 1 | 2020 | 67 | 0.680 |
Why?
|
Public Health | 1 | 2020 | 82 | 0.680 |
Why?
|
Follow-Up Studies | 16 | 2020 | 1269 | 0.660 |
Why?
|
Models, Theoretical | 2 | 2019 | 76 | 0.660 |
Why?
|
Mortality | 5 | 2019 | 123 | 0.640 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2020 | 760 | 0.640 |
Why?
|
Survivors | 5 | 2016 | 158 | 0.620 |
Why?
|
Models, Statistical | 4 | 2017 | 185 | 0.620 |
Why?
|
Survival Analysis | 13 | 2017 | 226 | 0.600 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 50 | 0.600 |
Why?
|
Multivariate Analysis | 10 | 2020 | 598 | 0.600 |
Why?
|
California | 13 | 2024 | 2365 | 0.590 |
Why?
|
United States | 23 | 2022 | 4164 | 0.580 |
Why?
|
Heart Failure | 3 | 2022 | 398 | 0.580 |
Why?
|
Weight Loss | 4 | 2016 | 321 | 0.570 |
Why?
|
European Continental Ancestry Group | 7 | 2019 | 554 | 0.560 |
Why?
|
African Americans | 5 | 2019 | 490 | 0.550 |
Why?
|
Aged, 80 and over | 14 | 2022 | 2003 | 0.520 |
Why?
|
Medical Records | 1 | 2015 | 106 | 0.510 |
Why?
|
Weight Gain | 5 | 2016 | 181 | 0.500 |
Why?
|
Muscle, Skeletal | 3 | 2020 | 32 | 0.490 |
Why?
|
Medication Adherence | 1 | 2018 | 267 | 0.490 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2024 | 73 | 0.490 |
Why?
|
Telomerase | 2 | 2011 | 6 | 0.490 |
Why?
|
Algorithms | 1 | 2015 | 241 | 0.470 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 34 | 0.460 |
Why?
|
Surveys and Questionnaires | 11 | 2023 | 1389 | 0.450 |
Why?
|
Biomarkers | 6 | 2018 | 308 | 0.450 |
Why?
|
Nurses | 4 | 2009 | 40 | 0.450 |
Why?
|
Leukocytes | 2 | 2015 | 9 | 0.430 |
Why?
|
Telomere Shortening | 2 | 2013 | 3 | 0.430 |
Why?
|
Coronary Disease | 6 | 2020 | 185 | 0.430 |
Why?
|
Caregivers | 3 | 2014 | 126 | 0.420 |
Why?
|
Diet, Reducing | 1 | 2012 | 27 | 0.420 |
Why?
|
Work Schedule Tolerance | 3 | 2006 | 7 | 0.420 |
Why?
|
Circadian Rhythm | 1 | 2012 | 17 | 0.420 |
Why?
|
Hot Flashes | 1 | 2012 | 39 | 0.410 |
Why?
|
Affect | 1 | 2012 | 26 | 0.410 |
Why?
|
Calcinosis | 1 | 2012 | 40 | 0.410 |
Why?
|
Triple Negative Breast Neoplasms | 2 | 2022 | 2 | 0.410 |
Why?
|
Risk Assessment | 11 | 2020 | 1143 | 0.400 |
Why?
|
Body Composition | 4 | 2021 | 82 | 0.400 |
Why?
|
Exercise | 7 | 2022 | 495 | 0.400 |
Why?
|
Vascular Calcification | 1 | 2011 | 9 | 0.400 |
Why?
|
Adrenal Cortex | 1 | 2011 | 1 | 0.400 |
Why?
|
Young Adult | 11 | 2024 | 2518 | 0.400 |
Why?
|
Mouth Mucosa | 1 | 2011 | 5 | 0.400 |
Why?
|
Autonomic Nervous System | 1 | 2011 | 3 | 0.400 |
Why?
|
Odds Ratio | 7 | 2015 | 701 | 0.400 |
Why?
|
Ethnic Groups | 2 | 2015 | 501 | 0.390 |
Why?
|
Biomarkers, Tumor | 3 | 2018 | 146 | 0.380 |
Why?
|
Male | 17 | 2021 | 10440 | 0.380 |
Why?
|
Socioeconomic Factors | 6 | 2019 | 673 | 0.370 |
Why?
|
Cause of Death | 5 | 2024 | 185 | 0.360 |
Why?
|
Health Behavior | 3 | 2020 | 374 | 0.350 |
Why?
|
Receptors, Progesterone | 4 | 2020 | 52 | 0.350 |
Why?
|
Health Status Indicators | 3 | 2009 | 71 | 0.340 |
Why?
|
Occupational Health | 2 | 2006 | 21 | 0.340 |
Why?
|
Cross-Sectional Studies | 7 | 2019 | 1360 | 0.340 |
Why?
|
Severity of Illness Index | 5 | 2018 | 476 | 0.340 |
Why?
|
Adiposity | 3 | 2020 | 67 | 0.340 |
Why?
|
Interpersonal Relations | 2 | 2020 | 42 | 0.330 |
Why?
|
Sarcopenia | 2 | 2020 | 11 | 0.330 |
Why?
|
Metabolic Syndrome | 2 | 2022 | 80 | 0.330 |
Why?
|
Inflammation | 3 | 2022 | 63 | 0.330 |
Why?
|
Social Class | 2 | 2017 | 125 | 0.320 |
Why?
|
Quality-Adjusted Life Years | 1 | 2008 | 41 | 0.310 |
Why?
|
Longitudinal Studies | 8 | 2016 | 724 | 0.310 |
Why?
|
Gonadal Steroid Hormones | 2 | 2006 | 33 | 0.300 |
Why?
|
Disease | 1 | 2007 | 5 | 0.300 |
Why?
|
Logistic Models | 9 | 2017 | 962 | 0.300 |
Why?
|
Sleep | 2 | 2019 | 57 | 0.300 |
Why?
|
Adolescent | 8 | 2016 | 3798 | 0.280 |
Why?
|
Depression | 3 | 2013 | 518 | 0.270 |
Why?
|
Occupational Exposure | 1 | 2006 | 67 | 0.270 |
Why?
|
Cancer Survivors | 2 | 2018 | 89 | 0.270 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2015 | 55 | 0.270 |
Why?
|
Health Status | 1 | 2007 | 328 | 0.250 |
Why?
|
Aging | 4 | 2014 | 165 | 0.250 |
Why?
|
Linear Models | 5 | 2019 | 243 | 0.250 |
Why?
|
Tomography, X-Ray Computed | 5 | 2020 | 208 | 0.240 |
Why?
|
Mastectomy | 1 | 2024 | 39 | 0.240 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 14 | 0.240 |
Why?
|
Disease Progression | 3 | 2013 | 271 | 0.240 |
Why?
|
Retrospective Studies | 8 | 2021 | 2550 | 0.240 |
Why?
|
Adenoma | 1 | 2005 | 100 | 0.240 |
Why?
|
Blood Glucose | 2 | 2012 | 346 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2018 | 342 | 0.230 |
Why?
|
Kaplan-Meier Estimate | 5 | 2017 | 131 | 0.230 |
Why?
|
Combined Modality Therapy | 3 | 2020 | 150 | 0.230 |
Why?
|
Life Change Events | 3 | 2024 | 31 | 0.220 |
Why?
|
Registries | 5 | 2020 | 490 | 0.220 |
Why?
|
Intra-Abdominal Fat | 2 | 2020 | 15 | 0.220 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2019 | 392 | 0.220 |
Why?
|
Colectomy | 2 | 2020 | 27 | 0.220 |
Why?
|
C-Reactive Protein | 3 | 2018 | 58 | 0.220 |
Why?
|
Comorbidity | 4 | 2020 | 619 | 0.220 |
Why?
|
Data Interpretation, Statistical | 1 | 2013 | 83 | 0.220 |
Why?
|
Hypoglycemic Agents | 2 | 2013 | 288 | 0.210 |
Why?
|
Age Factors | 7 | 2019 | 965 | 0.210 |
Why?
|
Survival Rate | 6 | 2020 | 269 | 0.210 |
Why?
|
Electronic Health Records | 3 | 2024 | 747 | 0.210 |
Why?
|
Time Factors | 6 | 2016 | 1136 | 0.210 |
Why?
|
Models, Structural | 1 | 2012 | 3 | 0.210 |
Why?
|
Smoking | 4 | 2012 | 494 | 0.210 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 333 | 0.200 |
Why?
|
Loneliness | 1 | 2022 | 6 | 0.200 |
Why?
|
Cognitive Dysfunction | 1 | 2023 | 47 | 0.200 |
Why?
|
Outcome and Process Assessment (Health Care) | 1 | 2012 | 110 | 0.200 |
Why?
|
Receptors, Estrogen | 2 | 2020 | 58 | 0.200 |
Why?
|
Cost of Illness | 2 | 2012 | 100 | 0.200 |
Why?
|
Dementia | 1 | 2023 | 105 | 0.190 |
Why?
|
Population Surveillance | 3 | 2016 | 271 | 0.180 |
Why?
|
Causality | 2 | 2019 | 43 | 0.180 |
Why?
|
China | 3 | 2016 | 130 | 0.180 |
Why?
|
Subcutaneous Fat, Abdominal | 1 | 2020 | 4 | 0.180 |
Why?
|
Alcohol Drinking | 1 | 2003 | 375 | 0.170 |
Why?
|
Confounding Factors (Epidemiology) | 3 | 2013 | 99 | 0.170 |
Why?
|
Health Status Disparities | 3 | 2021 | 153 | 0.170 |
Why?
|
Delivery of Health Care | 1 | 2023 | 444 | 0.160 |
Why?
|
Receptor, ErbB-2 | 4 | 2024 | 48 | 0.160 |
Why?
|
Genetic Predisposition to Disease | 3 | 2015 | 414 | 0.160 |
Why?
|
African Continental Ancestry Group | 2 | 2012 | 166 | 0.160 |
Why?
|
Treatment Outcome | 5 | 2020 | 1296 | 0.160 |
Why?
|
Insulin Resistance | 2 | 2017 | 129 | 0.160 |
Why?
|
Leukocyte Count | 1 | 2018 | 22 | 0.160 |
Why?
|
Estrogen Receptor alpha | 2 | 2015 | 27 | 0.150 |
Why?
|
Survivorship | 1 | 2018 | 9 | 0.150 |
Why?
|
Bias | 1 | 2018 | 111 | 0.150 |
Why?
|
Public Health Surveillance | 1 | 2018 | 45 | 0.150 |
Why?
|
Self Report | 3 | 2019 | 256 | 0.150 |
Why?
|
Vegetables | 3 | 2015 | 87 | 0.150 |
Why?
|
Pessimism | 1 | 2017 | 1 | 0.150 |
Why?
|
Optimism | 1 | 2017 | 2 | 0.150 |
Why?
|
Metabolic Diseases | 1 | 2017 | 4 | 0.150 |
Why?
|
Hostility | 1 | 2017 | 7 | 0.150 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2018 | 65 | 0.150 |
Why?
|
Marriage | 1 | 2017 | 7 | 0.150 |
Why?
|
Epidemiologic Methods | 1 | 2017 | 87 | 0.150 |
Why?
|
Overweight | 2 | 2016 | 276 | 0.140 |
Why?
|
Disease Management | 1 | 2018 | 143 | 0.140 |
Why?
|
Case-Control Studies | 3 | 2015 | 1173 | 0.140 |
Why?
|
Hospitalization | 2 | 2022 | 847 | 0.140 |
Why?
|
Patient Outcome Assessment | 1 | 2016 | 29 | 0.140 |
Why?
|
Analysis of Variance | 2 | 2017 | 167 | 0.140 |
Why?
|
Child | 3 | 2022 | 2571 | 0.140 |
Why?
|
Metabolic Equivalent | 1 | 2016 | 8 | 0.140 |
Why?
|
Pregnancy Rate | 1 | 2016 | 5 | 0.140 |
Why?
|
Reproduction | 1 | 2016 | 12 | 0.140 |
Why?
|
Outcome Assessment (Health Care) | 1 | 2018 | 254 | 0.140 |
Why?
|
Recurrence | 2 | 2014 | 187 | 0.140 |
Why?
|
Intraoperative Complications | 1 | 2016 | 5 | 0.140 |
Why?
|
Chi-Square Distribution | 2 | 2017 | 160 | 0.130 |
Why?
|
Longevity | 2 | 2022 | 13 | 0.130 |
Why?
|
Sleep Wake Disorders | 1 | 2016 | 38 | 0.130 |
Why?
|
Marital Status | 2 | 2013 | 22 | 0.130 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 65 | 0.130 |
Why?
|
Thinness | 2 | 2014 | 29 | 0.130 |
Why?
|
Mexican Americans | 1 | 2015 | 48 | 0.130 |
Why?
|
Ovarian Neoplasms | 1 | 2016 | 50 | 0.130 |
Why?
|
Child, Preschool | 2 | 2011 | 1478 | 0.130 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 321 | 0.120 |
Why?
|
Edible Grain | 2 | 2012 | 14 | 0.120 |
Why?
|
Fruit | 2 | 2012 | 79 | 0.120 |
Why?
|
Residence Characteristics | 1 | 2017 | 256 | 0.120 |
Why?
|
Geriatric Assessment | 1 | 2014 | 40 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2017 | 131 | 0.120 |
Why?
|
Stillbirth | 1 | 2014 | 30 | 0.120 |
Why?
|
Utah | 1 | 2014 | 33 | 0.120 |
Why?
|
Cognition Disorders | 2 | 2013 | 32 | 0.120 |
Why?
|
Testicular Neoplasms | 1 | 2013 | 11 | 0.120 |
Why?
|
Fluoxetine | 1 | 2013 | 26 | 0.120 |
Why?
|
Mobility Limitation | 1 | 2014 | 16 | 0.120 |
Why?
|
Abortion, Spontaneous | 1 | 2014 | 52 | 0.110 |
Why?
|
Social Environment | 2 | 2020 | 90 | 0.110 |
Why?
|
Paroxetine | 1 | 2013 | 23 | 0.110 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2013 | 28 | 0.110 |
Why?
|
Prevalence | 2 | 2017 | 911 | 0.110 |
Why?
|
Serotonin Uptake Inhibitors | 1 | 2013 | 74 | 0.110 |
Why?
|
Breast Feeding | 1 | 2015 | 133 | 0.110 |
Why?
|
Cellular Senescence | 1 | 2013 | 1 | 0.110 |
Why?
|
Apolipoprotein E4 | 1 | 2013 | 2 | 0.110 |
Why?
|
Heterozygote | 1 | 2013 | 29 | 0.110 |
Why?
|
Self Concept | 1 | 2013 | 42 | 0.110 |
Why?
|
Guideline Adherence | 3 | 2024 | 162 | 0.110 |
Why?
|
Patient Compliance | 2 | 2014 | 318 | 0.110 |
Why?
|
Sex Factors | 3 | 2020 | 661 | 0.110 |
Why?
|
Sweating | 1 | 2012 | 9 | 0.110 |
Why?
|
Neoplasm Invasiveness | 3 | 2017 | 83 | 0.110 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 119 | 0.110 |
Why?
|
Family Characteristics | 1 | 2012 | 54 | 0.100 |
Why?
|
Psychology | 2 | 2014 | 17 | 0.100 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2013 | 59 | 0.100 |
Why?
|
Radiography | 1 | 2012 | 41 | 0.100 |
Why?
|
Religion | 1 | 2012 | 14 | 0.100 |
Why?
|
Up-Regulation | 1 | 2011 | 7 | 0.100 |
Why?
|
Sex Distribution | 1 | 2012 | 198 | 0.100 |
Why?
|
Coronary Angiography | 1 | 2011 | 22 | 0.100 |
Why?
|
Selection Bias | 2 | 2019 | 24 | 0.100 |
Why?
|
Arrhythmia, Sinus | 1 | 2011 | 2 | 0.100 |
Why?
|
Disease-Free Survival | 3 | 2016 | 57 | 0.100 |
Why?
|
Saliva | 1 | 2011 | 12 | 0.100 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2011 | 13 | 0.100 |
Why?
|
Hydrocortisone | 1 | 2011 | 16 | 0.100 |
Why?
|
Atherosclerosis | 1 | 2012 | 51 | 0.100 |
Why?
|
Heart Rate | 1 | 2011 | 40 | 0.100 |
Why?
|
Health Surveys | 2 | 2018 | 269 | 0.100 |
Why?
|
Family | 1 | 2012 | 120 | 0.090 |
Why?
|
Chronic Disease | 1 | 2014 | 468 | 0.090 |
Why?
|
Regression Analysis | 3 | 2011 | 319 | 0.090 |
Why?
|
Anxiety | 1 | 2011 | 156 | 0.090 |
Why?
|
Lymphocyte Subsets | 1 | 2009 | 2 | 0.090 |
Why?
|
B-Lymphocytes | 1 | 2009 | 4 | 0.090 |
Why?
|
T-Lymphocytes | 1 | 2009 | 8 | 0.090 |
Why?
|
DNA | 1 | 2009 | 25 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 2009 | 36 | 0.080 |
Why?
|
Waist Circumference | 2 | 2022 | 38 | 0.080 |
Why?
|
SEER Program | 2 | 2020 | 101 | 0.080 |
Why?
|
Activities of Daily Living | 1 | 2008 | 96 | 0.080 |
Why?
|
Stroke | 3 | 2016 | 311 | 0.080 |
Why?
|
Psychosocial Deprivation | 1 | 2007 | 4 | 0.080 |
Why?
|
Depressive Disorder, Major | 1 | 2009 | 127 | 0.080 |
Why?
|
Dietary Fiber | 2 | 2015 | 60 | 0.080 |
Why?
|
Child Development | 1 | 2007 | 52 | 0.070 |
Why?
|
Attitude to Health | 1 | 2008 | 177 | 0.070 |
Why?
|
Insulin | 2 | 2015 | 208 | 0.070 |
Why?
|
Risk | 3 | 2017 | 552 | 0.070 |
Why?
|
Melatonin | 1 | 2006 | 4 | 0.070 |
Why?
|
Reproductive History | 1 | 2006 | 18 | 0.070 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2006 | 43 | 0.070 |
Why?
|
Complementary Therapies | 1 | 2006 | 50 | 0.070 |
Why?
|
Meat | 1 | 2005 | 27 | 0.070 |
Why?
|
Community Networks | 1 | 2006 | 28 | 0.070 |
Why?
|
Aircraft | 1 | 2005 | 3 | 0.070 |
Why?
|
Confidence Intervals | 2 | 2016 | 253 | 0.060 |
Why?
|
Occupational Diseases | 1 | 2005 | 42 | 0.060 |
Why?
|
Databases, Factual | 2 | 2017 | 327 | 0.060 |
Why?
|
Income | 2 | 2017 | 98 | 0.060 |
Why?
|
Nursing | 1 | 2004 | 2 | 0.060 |
Why?
|
Educational Status | 2 | 2017 | 205 | 0.060 |
Why?
|
Trastuzumab | 1 | 2024 | 17 | 0.060 |
Why?
|
Drug Combinations | 1 | 2024 | 43 | 0.060 |
Why?
|
C-Peptide | 1 | 2003 | 6 | 0.060 |
Why?
|
Self Efficacy | 1 | 2004 | 71 | 0.060 |
Why?
|
Sulfonylurea Compounds | 1 | 2013 | 28 | 0.060 |
Why?
|
Temperance | 1 | 2003 | 24 | 0.060 |
Why?
|
Colonoscopy | 1 | 2005 | 268 | 0.060 |
Why?
|
Metformin | 1 | 2013 | 61 | 0.050 |
Why?
|
Waist-Hip Ratio | 1 | 2022 | 23 | 0.050 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 77 | 0.050 |
Why?
|
Glomerular Filtration Rate | 1 | 2013 | 157 | 0.050 |
Why?
|
Albuminuria | 1 | 2012 | 41 | 0.050 |
Why?
|
Cognition | 1 | 2022 | 82 | 0.050 |
Why?
|
Computer Simulation | 1 | 2012 | 85 | 0.050 |
Why?
|
Narration | 1 | 2021 | 11 | 0.050 |
Why?
|
Emotions | 1 | 2021 | 35 | 0.050 |
Why?
|
Glycated Hemoglobin A | 1 | 2012 | 233 | 0.050 |
Why?
|
Hypertension | 1 | 2005 | 524 | 0.050 |
Why?
|
Preoperative Care | 1 | 2020 | 19 | 0.050 |
Why?
|
Morbidity | 1 | 2020 | 62 | 0.050 |
Why?
|
Diabetic Angiopathies | 1 | 2020 | 36 | 0.040 |
Why?
|
Length of Stay | 1 | 2020 | 183 | 0.040 |
Why?
|
Pregnancy | 2 | 2016 | 1516 | 0.040 |
Why?
|
Angina, Unstable | 1 | 1999 | 7 | 0.040 |
Why?
|
Qualitative Research | 1 | 2021 | 272 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2019 | 94 | 0.040 |
Why?
|
Health Communication | 1 | 2019 | 16 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2019 | 120 | 0.040 |
Why?
|
Patient Readmission | 1 | 2020 | 162 | 0.040 |
Why?
|
Adipose Tissue | 1 | 2018 | 60 | 0.040 |
Why?
|
Probability | 1 | 2018 | 86 | 0.040 |
Why?
|
Pilot Projects | 1 | 2019 | 237 | 0.040 |
Why?
|
Breast Carcinoma In Situ | 1 | 2018 | 2 | 0.040 |
Why?
|
Body Height | 1 | 2018 | 62 | 0.040 |
Why?
|
Telephone | 1 | 2019 | 179 | 0.040 |
Why?
|
Occupations | 1 | 2017 | 16 | 0.040 |
Why?
|
Observational Studies as Topic | 1 | 2018 | 49 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2017 | 3 | 0.040 |
Why?
|
Leucovorin | 1 | 2017 | 5 | 0.040 |
Why?
|
Organ Size | 1 | 2017 | 16 | 0.040 |
Why?
|
Statistics, Nonparametric | 1 | 2017 | 51 | 0.040 |
Why?
|
Fluorouracil | 1 | 2017 | 12 | 0.040 |
Why?
|
Withholding Treatment | 1 | 2017 | 26 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 100 | 0.040 |
Why?
|
Myocardial Infarction | 1 | 1999 | 249 | 0.040 |
Why?
|
Fast Foods | 1 | 2017 | 12 | 0.040 |
Why?
|
Insurance Claim Review | 1 | 2016 | 70 | 0.030 |
Why?
|
Phenotype | 1 | 2017 | 148 | 0.030 |
Why?
|
Snoring | 1 | 2016 | 1 | 0.030 |
Why?
|
Protective Factors | 1 | 2016 | 33 | 0.030 |
Why?
|
Heart Valve Diseases | 1 | 2016 | 20 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2016 | 32 | 0.030 |
Why?
|
Nutritional Status | 1 | 2016 | 30 | 0.030 |
Why?
|
Mexico | 1 | 2015 | 20 | 0.030 |
Why?
|
Dietary Proteins | 1 | 2015 | 20 | 0.030 |
Why?
|
Dietary Carbohydrates | 1 | 2015 | 27 | 0.030 |
Why?
|
Diet Records | 1 | 2015 | 36 | 0.030 |
Why?
|
Culture | 1 | 2015 | 29 | 0.030 |
Why?
|
Food | 1 | 2015 | 31 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2015 | 20 | 0.030 |
Why?
|
Gait | 1 | 2014 | 7 | 0.030 |
Why?
|
Hand Strength | 1 | 2014 | 11 | 0.030 |
Why?
|
Exercise Test | 1 | 2014 | 45 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2014 | 20 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 27 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 365 | 0.030 |
Why?
|
Obesity, Abdominal | 1 | 2014 | 11 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2014 | 49 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2014 | 80 | 0.030 |
Why?
|
Hormone Replacement Therapy | 1 | 2013 | 28 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2013 | 38 | 0.030 |
Why?
|
Alleles | 1 | 2013 | 95 | 0.030 |
Why?
|
Genotype | 1 | 2013 | 253 | 0.030 |
Why?
|
Alzheimer Disease | 1 | 2013 | 43 | 0.030 |
Why?
|
Continental Population Groups | 1 | 2014 | 315 | 0.020 |
Why?
|
Blood Pressure | 2 | 2005 | 310 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2013 | 211 | 0.020 |
Why?
|
Hispanic Americans | 1 | 2013 | 428 | 0.020 |
Why?
|
Estrogen Replacement Therapy | 1 | 2010 | 104 | 0.020 |
Why?
|
Antigens, CD | 1 | 2009 | 5 | 0.020 |
Why?
|
Obesity, Morbid | 1 | 2011 | 120 | 0.020 |
Why?
|
Motor Activity | 1 | 2011 | 215 | 0.020 |
Why?
|
Menopause | 1 | 2006 | 72 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 199 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2007 | 259 | 0.010 |
Why?
|
Digitalis Glycosides | 1 | 1999 | 1 | 0.010 |
Why?
|
Forms and Records Control | 1 | 1999 | 7 | 0.010 |
Why?
|
Shock, Cardiogenic | 1 | 1999 | 6 | 0.010 |
Why?
|
Death Certificates | 1 | 1999 | 19 | 0.010 |
Why?
|
Minnesota | 1 | 1999 | 54 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 1999 | 21 | 0.010 |
Why?
|
Lipids | 1 | 1999 | 78 | 0.010 |
Why?
|
Data Collection | 1 | 1999 | 275 | 0.010 |
Why?
|
Patient Discharge | 1 | 1999 | 153 | 0.010 |
Why?
|